title: Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions.
abstract: OBJECTIVE
  To determine the effects of long-term, low-dose difluoromethylornithine (DFMO) on audiometric thresholds and distortion product otoacoustic emission (DPOAE) levels in humans.
  
  
  METHODS
  A prospective, randomized, placebo-controlled phase 2 clinical trial of DFMO in participants with a prior adenomatous colonic polyp.
  
  
  METHODS
  Academic tertiary care referral center.
  
  
  METHODS
  One hundred twenty-three volunteer subjects with colorectal polyps and normal hearing for the frequencies 250 through 2000 Hz.
  
  
  METHODS
  Subjects were randomized to receive placebo or oral DFMO at daily dosages between 0.075 and 0.4 g/m(2) of body surface area for 12 months.
  
  
  METHODS
  Pure-tone audiometric thresholds for the frequencies 250, 500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz and DPOAE levels were measured at baseline and 1, 3, 6, 9, and 12 months after starting treatment with DFMO or placebo and 3 months after cessation of treatment if there was a suggestion of possible changes at the 12-month measurement.
  
  
  RESULTS
  At these low dosages, there was little evidence for shifts in auditory pure-tone thresholds, and there were no statistically significant shifts in DPOAE levels. For auditory pure-tone thresholds, there was a subtle, approximately 2- to 3-dB hearing level decrease in hearing sensitivity for the 2 higher DFMO dosages, but only at the 2 lowest frequencies, 250 and 500 Hz.
  
  
  CONCLUSIONS
  Administration of low-dose DFMO for 12 months did not produce hearing loss, in contrast to prior studies that used higher dosages.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, University of California Davis Medical Center, Sacramento, CA 95817, USA. karen.doyle@ucdmc.ucdavis.edu
authors.forename: K J
authors.initials: KJ
authors.lastname: Doyle
authors.forename: C E
authors.initials: CE
authors.lastname: McLaren
authors.forename: J E
authors.initials: JE
authors.lastname: Shanks
authors.forename: C M
authors.initials: CM
authors.lastname: Galus
authors.forename: F L
authors.initials: FL
authors.lastname: Meyskens
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects*; D003111:Colonic Polyps / Q000188:drug therapy; D015179:Colorectal Neoplasms / Q000178:diet therapy; D003638:Deafness / Q000517:prevention & control*; D000518:Eflornithine / Q000008:administration & dosage*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D006801:Humans; D065108:Ornithine Decarboxylase Inhibitors; D017084:Otoacoustic Emissions, Spontaneous / Q000187:drug effects*; D011446:Prospective Studies
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D065108:Ornithine Decarboxylase Inhibitors; D000518:Eflornithine